Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.55 HKD | +1.35% | +10.27% | +10.27% |
May. 14 | China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status | MT |
Apr. 29 | Wall Street Cues, Property Outlooks Lift Asian Stock Markets | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its low valuation, with P/E ratio at 7.3 and 6.64 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The stock, which is currently worth 2024 to 0.13 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.27% | 8.89B | C | ||
+19.14% | 72.09B | C+ | ||
-3.34% | 23.88B | C+ | ||
+12.67% | 8.46B | B | ||
-17.41% | 8.29B | B- | ||
+9.65% | 4.9B | B- | ||
+21.40% | 4.34B | B+ | ||
-1.41% | 3.98B | B- | ||
-1.99% | 3.89B | B | ||
+27.43% | 3.86B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1099 Stock
- Ratings Sinopharm Group Co. Ltd.